The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia

Diana Z Paderina; Anastasiia S Boiko; Ivan V Pozhidaev; Irina A Mednova; Anastasia A Goncharova; Anna V Bocharova; Olga Yu Fedorenko; Elena G Kornetova; Arkadiy V Semke; Nikolay A Bokhan; Anton J M Loonen; Svetlana A Ivanova

doi:10.3390/genes13081312

The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia

Diana Z Paderina, Anastasiia S Boiko, Ivan V Pozhidaev, Irina A Mednova, Anastasia A Goncharova, Anna V Bocharova, Olga Yu Fedorenko, Elena G Kornetova, Arkadiy V Semke, Nikolay A Bokhan, Anton J M Loonen^*, Svetlana A Ivanova

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

87 Downloads (Pure)

Abstract

BACKGROUND: Metabolic syndrome is widespread in patients with schizophrenia receiving long-term antipsychotic therapy. Dopamine D2 receptors play an important role in mediating both the therapeutic actions of antipsychotics and their side effects. The present study examined the association of two polymorphisms of the DRD2 gene with metabolic syndrome in patients with schizophrenia.

METHODS: We examined 517 patients from several regions of Siberia (Russia) with a clinical diagnosis of schizophrenia. Genotyping of two single nucleotide polymorphisms rs1799732 and rs4436578 of the dopamine D2 receptor gene (DRD2) was performed in a population of 471 patients. The results were analyzed using chi-square tests.

RESULTS: Functional polymorphism rs1799732 of the DRD2 gene is associated with drug-induced metabolic syndrome in women with schizophrenia.

CONCLUSIONS: Our results show that the DRD2 gene may be involved in the pathogenesis of metabolic disorders in patients with schizophrenia. Further analysis of possible genetic markers will allow for personalized treatment with minimal side effects and optimal efficacy. This which seems relevant in light of the recent focus on improving the quality of life and ensuring a high level of social adaptation of patients with schizophrenia.

Original language	English
Article number	1312
Number of pages	12
Journal	Genes
Volume	13
Issue number	8
DOIs	https://doi.org/10.3390/genes13081312
Publication status	Published - 23-Jul-2022

Keywords

Antipsychotic Agents/adverse effects
Female
Humans
Metabolic Syndrome/genetics
Polymorphism, Single Nucleotide/genetics
Quality of Life
Receptors, Dopamine D2/genetics
Schizophrenia/drug therapy

Access to Document

10.3390/genes13081312Licence: CC BY

The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with SchizophreniaFinal publisher's version, 289 KBLicence: CC BY

Handle.net

Persistent link

Cite this

Paderina, D. Z., Boiko, A. S., Pozhidaev, I. V., Mednova, I. A., Goncharova, A. A., Bocharova, A. V., Fedorenko, O. Y., Kornetova, E. G., Semke, A. V., Bokhan, N. A., Loonen, A. J. M., & Ivanova, S. A. (2022). The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia. Genes, 13(8), Article 1312. https://doi.org/10.3390/genes13081312

@article{6a46b90529e84eacac387e520ea78fe3,

title = "The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia",

abstract = "BACKGROUND: Metabolic syndrome is widespread in patients with schizophrenia receiving long-term antipsychotic therapy. Dopamine D2 receptors play an important role in mediating both the therapeutic actions of antipsychotics and their side effects. The present study examined the association of two polymorphisms of the DRD2 gene with metabolic syndrome in patients with schizophrenia.METHODS: We examined 517 patients from several regions of Siberia (Russia) with a clinical diagnosis of schizophrenia. Genotyping of two single nucleotide polymorphisms rs1799732 and rs4436578 of the dopamine D2 receptor gene (DRD2) was performed in a population of 471 patients. The results were analyzed using chi-square tests.RESULTS: Functional polymorphism rs1799732 of the DRD2 gene is associated with drug-induced metabolic syndrome in women with schizophrenia.CONCLUSIONS: Our results show that the DRD2 gene may be involved in the pathogenesis of metabolic disorders in patients with schizophrenia. Further analysis of possible genetic markers will allow for personalized treatment with minimal side effects and optimal efficacy. This which seems relevant in light of the recent focus on improving the quality of life and ensuring a high level of social adaptation of patients with schizophrenia.",

keywords = "Antipsychotic Agents/adverse effects, Female, Humans, Metabolic Syndrome/genetics, Polymorphism, Single Nucleotide/genetics, Quality of Life, Receptors, Dopamine D2/genetics, Schizophrenia/drug therapy",

author = "Paderina, {Diana Z} and Boiko, {Anastasiia S} and Pozhidaev, {Ivan V} and Mednova, {Irina A} and Goncharova, {Anastasia A} and Bocharova, {Anna V} and Fedorenko, {Olga Yu} and Kornetova, {Elena G} and Semke, {Arkadiy V} and Bokhan, {Nikolay A} and Loonen, {Anton J M} and Ivanova, {Svetlana A}",

year = "2022",

month = jul,

day = "23",

doi = "10.3390/genes13081312",

language = "English",

volume = "13",

journal = "Genes",

issn = "2073-4425",

publisher = "MDPI AG",

number = "8",

}

TY - JOUR

T1 - The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia

AU - Paderina, Diana Z

AU - Boiko, Anastasiia S

AU - Pozhidaev, Ivan V

AU - Mednova, Irina A

AU - Goncharova, Anastasia A

AU - Bocharova, Anna V

AU - Fedorenko, Olga Yu

AU - Kornetova, Elena G

AU - Semke, Arkadiy V

AU - Bokhan, Nikolay A

AU - Loonen, Anton J M

AU - Ivanova, Svetlana A

PY - 2022/7/23

Y1 - 2022/7/23

N2 - BACKGROUND: Metabolic syndrome is widespread in patients with schizophrenia receiving long-term antipsychotic therapy. Dopamine D2 receptors play an important role in mediating both the therapeutic actions of antipsychotics and their side effects. The present study examined the association of two polymorphisms of the DRD2 gene with metabolic syndrome in patients with schizophrenia.METHODS: We examined 517 patients from several regions of Siberia (Russia) with a clinical diagnosis of schizophrenia. Genotyping of two single nucleotide polymorphisms rs1799732 and rs4436578 of the dopamine D2 receptor gene (DRD2) was performed in a population of 471 patients. The results were analyzed using chi-square tests.RESULTS: Functional polymorphism rs1799732 of the DRD2 gene is associated with drug-induced metabolic syndrome in women with schizophrenia.CONCLUSIONS: Our results show that the DRD2 gene may be involved in the pathogenesis of metabolic disorders in patients with schizophrenia. Further analysis of possible genetic markers will allow for personalized treatment with minimal side effects and optimal efficacy. This which seems relevant in light of the recent focus on improving the quality of life and ensuring a high level of social adaptation of patients with schizophrenia.

AB - BACKGROUND: Metabolic syndrome is widespread in patients with schizophrenia receiving long-term antipsychotic therapy. Dopamine D2 receptors play an important role in mediating both the therapeutic actions of antipsychotics and their side effects. The present study examined the association of two polymorphisms of the DRD2 gene with metabolic syndrome in patients with schizophrenia.METHODS: We examined 517 patients from several regions of Siberia (Russia) with a clinical diagnosis of schizophrenia. Genotyping of two single nucleotide polymorphisms rs1799732 and rs4436578 of the dopamine D2 receptor gene (DRD2) was performed in a population of 471 patients. The results were analyzed using chi-square tests.RESULTS: Functional polymorphism rs1799732 of the DRD2 gene is associated with drug-induced metabolic syndrome in women with schizophrenia.CONCLUSIONS: Our results show that the DRD2 gene may be involved in the pathogenesis of metabolic disorders in patients with schizophrenia. Further analysis of possible genetic markers will allow for personalized treatment with minimal side effects and optimal efficacy. This which seems relevant in light of the recent focus on improving the quality of life and ensuring a high level of social adaptation of patients with schizophrenia.

KW - Antipsychotic Agents/adverse effects

KW - Female

KW - Humans

KW - Metabolic Syndrome/genetics

KW - Polymorphism, Single Nucleotide/genetics

KW - Quality of Life

KW - Receptors, Dopamine D2/genetics

KW - Schizophrenia/drug therapy

U2 - 10.3390/genes13081312

DO - 10.3390/genes13081312

M3 - Article

C2 - 35893053

SN - 2073-4425

VL - 13

JO - Genes

JF - Genes

IS - 8

M1 - 1312

ER -

The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this